Prelude Therapeutics Inc (PRLD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Prelude Therapeutics Inc stock (PRLD) is currently trading at $3.26. Prelude Therapeutics Inc PS ratio (Price-to-Sales) is 16.36. Analyst consensus price target for PRLD is $5.17. WallStSmart rates PRLD as Sell.
- PRLD PE ratio analysis and historical PE chart
- PRLD PS ratio (Price-to-Sales) history and trend
- PRLD intrinsic value — DCF, Graham Number, EPV models
- PRLD stock price prediction 2025 2026 2027 2028 2029 2030
- PRLD fair value vs current price
- PRLD insider transactions and insider buying
- Is PRLD undervalued or overvalued?
- Prelude Therapeutics Inc financial analysis — revenue, earnings, cash flow
- PRLD Piotroski F-Score and Altman Z-Score
- PRLD analyst price target and Smart Rating
Prelude Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Prelude Therapeutics Inc (PRLD) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Prelude Therapeutics Inc (PRLD) Key Strengths (2)
Revenue surging 41.00% year-over-year
59.16% held by institutions, strong professional interest
Supporting Valuation Data
Prelude Therapeutics Inc (PRLD) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 16.4x annual revenue
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Supporting Valuation Data
Prelude Therapeutics Inc (PRLD) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 41.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (16.36), Price/Book (2.71) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -99.50%, Operating Margin at -284.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -99.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 41.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PRLD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PRLD's Price-to-Sales ratio of 16.36x trades at a 41% premium to its historical average of 11.58x (62th percentile). The current valuation is 17% below its historical high of 19.73x set in Mar 2026, and 244% above its historical low of 4.75x in Feb 2025. Over the past 12 months, the PS ratio has expanded from ~5.0x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Prelude Therapeutics Inc (PRLD) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Prelude Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 12M with 41% growth year-over-year.
Key Findings
Revenue growing at 41% YoY, reaching 12M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Generating 23M in free cash flow and 23M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Growth sustainability: can Prelude Therapeutics Inc maintain 41%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Prelude Therapeutics Inc.
Bottom Line
Prelude Therapeutics Inc is a high-conviction growth story with revenue accelerating at 41% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(4 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:06:58 AM
About Prelude Therapeutics Inc(PRLD)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.